Current and Emerging Therapies for Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Program Overview

Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.

Credit Expired

Target Audience

Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
  • Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT

Activity Faculty


Doris M. Ponce, MD

Associate Professor, Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).


Christine N. Duncan, MD

Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA

Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources